Link to FLCCC ALLIANCE I-RECOVER POST-VACCINE TREATMENT PROTOCOL.
"Major public health authorities do not recognize post-COVID-vaccine injuries; and there is no specific ICD classification code for this disease. However, while no official definition exists, a temporal correlation between receiving a COVID-19 vaccine and beginning or worsening of a patient's clinical manifestations is sufficient to diagnose as a COVID-19 vaccine-induced injury, when the symptoms are unexplained by other concurrent causes.
Early treatment is essential; it is likely that the response to treatment will be attenuated when treatment is delayed."

Although Ivermectin has not been authorised in many Western countries against COVID-19, many countries permit its use against parasite diseases.
This web-page shows reports where ivermectin has had great success in reducing illnes, hospitalisation and death for patients with COVID-19.

All reports and text in this website are supported by links to their sources, while any personal comments are in red in italics. Please click on the bold dark blue text which are links which will take you to the source data, so that you can evaluate its veracity yourself.
Further below see possible reasons for resistance to administering ivermectin.
There are also pages on this website about other promising drugs and vitamins that may treat Covid-19.

For an excellent article that anyone can understand on ivermectin by Sameena Amien and FAIRLADY here is a link to the pdf.

This is an absolutely excellent short documentary (just 13 minutes) on Ivermectin and what THEY did to keep it from you and me. Please forward it to anyone that has ever mentioned "horse" in the same sentence as Ivermectin.

Reports of Ivermectin's success against Covid-19

Dr. Mark Trozzi on how well Ivermectin works, and other fascinating information on Ivermectin.

Journal Says Ivermectin Study Met Standard for 'Credible Science'. Medscape Tuesday, October 18, 2022.
A journal editor is defending his decision to publish a new paper showing that ivermectin can prevent Covid-19, despite more than a dozen retractions of such papers from the literature. The article, "Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects, " appeared in Cureus August 31 2022.

Conclusion: In this large PSM study, regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization, and mortality rates. Published: January 15, 2022.
The regular use of ivermectin led to a 68% reduction in COVID-19 mortality (25 [0.8%] versus 79 [2.6%] among ivermectin non-users; RR, 0.32; 95% CI, 0.20-0.49; p < 0.0001). When adjusted for residual variables, reduction in mortality rate was 70% (RR, 0.30; 95% CI, 0.19-0.46; p < 0.0001). There was a 56% reduction in hospitalization rate (44 versus 99 hospitalizations among ivermectin users and non-users, respectively; RR, 0.44; 95% CI, 0.31-0.63; p < 0.0001). After adjustment for residual variables, reduction in hospitalization rate was 67% (RR, 0.33; 95% CI, 023-0.66; p < 0.0001).
Note that this study was specifically for ivermectin as a prophylactic, as usage was discontinued when subjects tested positive to COVID-19

Ivermectin saves India - Jun 14, 2021.
Those Indian states that adopted more aggressive Ivermectin policies saw their cases fall far more than 80%, states like Uttar Pradesh - down 98% - 37,944 to 596, Uttarakhand - down 97% - 9642 to 287 and Goa - down 90% - 4195 to 423. Delhi saw a 99% drop - 28,395 to 238.
Tamil Nadu, which publicly banned Ivermectin, saw their cases rise to the highest in India, and they continued setting state records as at May 21, 2021, when they peaked at 36,184. By contrast, Tamil Nadu's deaths rose ten-fold from April 20 to May 27. On June 9, Tamil Nadu's COVID-19 deaths remained the second highest in India at 405, while the states that chose Ivermectin were all dramatically better.
The bottom line is that Ivermectin works, and it works extraordinarily well.

Ivermectin is effective for COVID-19: real-time meta-analysis of 99 studies and growing with 137,255 patients in 24 Countries as at 9 October 2023 with more appearing regularly.
As at 83%, 63% and 39% improvement for prophylaxis, early treatment and late treatment.
Random effects meta-analysis for early treatment and pooled effects shows a reduction of 83%, RR 0.17 [0.11-0.28].
Prophylactic use shows a reduction of 83%, RR 0.11 [0.05-0.23].
Mortality results show 78% lower mortality, RR 0.22 [0.12-0.41] for all treatment delays, and 86% lower, RR 0.14 [0.03-0.62] for early treatment.
100% of the 24 Randomized Controlled Trials (RCTs) report positive effects, with an estimated reduction of 72%, RR 0.28 [0.17-0.47].
The probability that an ineffective treatment generated results as positive as the 60 studies to date is estimated to be 1 in 9 trillion (p = 0.00000000000009).

Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally

https://www.medpagetoday.com/special-reports/exclusives/93485?xid=nl_popmed_2021-07-09&eun=g1631938d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=PopMedicine_070921&utm_term=NL_Gen_Int_PopMedicine_Active to treat SARS-CoV-2 infection by Andrew Hill, published 6 July 2021 in Open Forum Infectious Diseases.
In 11 randomized trials of moderate/severe infection, there was a 56% reduction in mortality, with favorable clinical recovery and reduced hospitalization. As for moderate disease, they reported a 70% improvement in survival with ivermectin. Use of ivermectin was also associated with a reduction in time to recovery of 1.58 days compared with controls with a shorter duration of hospitalization.

Click here for Prof Eli Schwartz pre-presentation of the Sheba Ivermectin Project, claimed to be the "first world, randomised, double-blind placebo-control (RDBPC) trial" now published in MedRxiv and in Israel - Sheba Ivermectin Project - previewed February 2021. Sheba Medical Center is the largest hospital in Israel, which Newsweek ranked it as the 9th-best hospital in the world. The objectives were to evaluate the reduction in viral shedding among mild to moderate Covid-19 patients and to evaluate the effect of preventing the progression of clinical disease.
Prof Schartz shows figures that prove that ivermectin was successful in both instances.
.

Dr Andrew Hill from Liverpool recently presented his meta-analysis data on the use of ivermectin in Covid-19, with a total of 7,100 patients from 53 available clinical trials. Many of these trials were the same as those in the more current above paragraph.
This meta-analysis investigated ivermectin in 18 randomised clinical trials (2282 patients) identified through systematic searches of PUBMED, EMBASE, MedRxiv and trial registries. Ivermectin was associated with reduced inflammatory markers (C-Reactive Protein, d-dimer and ferritin) and faster viral clearance by PCR. Viral clearance was treatment dose- and duration-dependent. In six randomised trials of moderate or severe infection, there was a 75% reduction in mortality.
"Across these six trials in 1255 patients, there were 14/658 (2.1%) deaths in the ivermectin arms, versus 57/597 (9.5%) deaths in the control arms. A combined analysis using inverse variance weighting ivermectin showed a 75% improvement in survival (RR 0.25 [95%CI 0.12-0.52]; p=0.0002, Figure 2). Heterogeneity was moderate, I 2 = 34%."

FLCCC Alliance Response to the NIH Guideline Committee Recommendation on Ivermectin use in COVID-19 dated January 14th, 2021
Last month, Dr Kory and his team testified before the U.S. Senate Homeland Security Committee in favour of authorising ivermectin, a Nobel Prize-winning antiparasitic agent, for early treatment of the novel coronavirus. In his impassioned presentation, Dr Kory explained that Ivermectin "basically obliterates transmission of this virus" with "miraculous effectiveness." Ivermectin has been the subject of dozens of studies and anecdotal success stories since it was found to reduce COVID-19 in a laboratory last June.
"I've been treating COVID pretty much every single day since the onset," Kory said at the December hearing. "When I say 'miracle', I do not use that term lightly. Mountains of data that has emerged in the last three months." Such data emanates from places like India, the second most populated nation in the world, which embraced the treatment protocol advanced by FLCCC and has watched its case and fatalities rate drop-in "steep decline." As of the end of June 2021, India has 285 Covid-9 deaths per million, while the USA has 1,860 per million, about six times the mortality.
Other examples come from Bangladesh, Peru, Argentina, Brazil and several other South American countries, all of which have demonstrated the effectiveness of ivermectin.
Dr. Pierre Kory Talks Covid-19, Ivermectin and the FLCCC
FLCCC Alliance press conference from Houston, Texas -5 December 2021. Includes dosages and explains that giving a placebo with the observational evidence is unethical. FLCCC Weekly Updates & Special Events

The National Institutes of Health (NIH) has upgraded their recommendation for ivermectin, making it an option for use in treating COVID-19 - Jan 19, 2021.
The result comes one week after Dr Paul Marik and Dr Pierre Kory - founding members of the FLCCC, along with Dr Andrew Hill, researcher and consultant to the World Health Organization (WHO), presented their data before the NIH Treatment Guidelines Panel.

"We See That This Works" "People are dying," Dr Marik said during a phone interview. "We treat patients at the bedside. We don't have the ivory tower syndrome where you tell people what to do though you have no idea what you're doing." "I could not have a patient admitted to my care and give placebo knowing what I know about ivermectin." Steven Joffe, MD, MPH, a medical ethicist at the University of Pennsylvania, said he doesn't believe clinicians "should be lowering our standards of evidence because we're in a pandemic."
Group members, mostly critical care physicians, don't see a need for more data and argue it would be unethical to give a placebo to patients given ivermectin's established safety. But that's raising more than a few eyebrows among others in the field. Marik said the group adapted the protocol for COVID-19, using a potent steroid and adding an anticoagulant, along with other elements. The new name was MATH+, for methylprednisolone, ascorbic acid, thiamine, and heparin, plus a statin, zinc, vitamin D, famotidine, melatonin, and magnesium.

Video by Dr Chris Martenson - Tuesday, December 8, 2020, when he goes through the ivermectin studies. Warning! This video was banned by YouTube.

Not Using Ivermectin, One Year In, Is Unethical And Immoral Incomprehensibly, the people we should trust to make the call on ivermectin are paralyzed by indecision and cowardice. For eight months, while hundreds of thousands died, the National Institutes of Health advised against using ivermectin except in clinical trials. Last week, NIH brushed aside evidence of efficacy in several thousand patients who took ivermectin and decreed there was "insufficient data to recommend either for or against."
80-year-old Buffalo Judith Smentkiewicz was on a ventilator with Covid-19 when her loved ones were told she'd likely spend another month in the ICU, where they gave her a 20 per cent chance of survival. The family did some research on ivermectin's success. They pressed an ICU doctor to give it, and, on day 12 of infection, he did. Within 48 hours of a single dose, Mrs Smentkiewicz had improved so much that she was moved out of critical care. But doctors on the new unit declined to continue ivermectin even as the woman's condition declined. The drug is not approved for COVID; they told her family. The family went to court, and the judge ordered the treatment resumed, and Mrs Smentkiewicz was released to a rehabilitation facility shortly. "It is a miracle from where she was." the family's attorney said.

NIH COVID-19 Treatment Guidelines Panel cannot draw definitive conclusions on the clinical efficacy of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide further guidance on the role of ivermectin in the treatment of COVID-19. Ivermectin: Selected Clinical Data - February 11, 2021

Potential to save lives: An intensive care doctor argues for 'compassionate use' of ivermectin for Covid-19 - By Nathi Mdladla, 15 January 2021
Ivermectin, an antiparasitic (anti-helminthic) used for various parasitic diseases in humans and animals, has been extensively investigated in this drug. The drug was not registered for human use in South Africa, but it is in many other countries, including the U.S., and "off-label" use is common.

As the Ivermectin effort during the pandemic reminded Dr. Tess Lawrie of her work in South Africa, where there were known drugs that could help large numbers of people, yet they couldn't access such drugs, she sprung into action during the Holiday Season, reviewing the work of the FLCCC and others and putting together what has become a compelling work. Dr Lawrie states the data is clear that ivermectin markedly reduces the COVID-19 death rate. Hence, any debate about clinical trials at this point should be secondary to figuring out how to accelerate emergency use as a complement to vaccines and other protective measures against the coronavirus.

At the conclusion of the January 14 BIRD conference, Dr. Lawrie delivered a monumental closing address that should be recorded among the most important speeches in the annals of medical history. Dr. Lawrie spoke out at considerable personal risk, since her livelihood and career largely rely on the very agencies she targeted for criticism.
Dr. Lawrie began by endorsing the miraculous efficacy of IVM. Had ivermectin been employed in 2020 when medical colleagues around the world first alerted the authorities to its efficacy, millions of lives could have been saved, and the pandemic with all its associated suffering and loss brought to a rapid and timely end. Dr. Lawrie told the audience that the suppression of ivermectin was a signal that Pharma's pervasive corruption had turned a medical cartel against patients and against humanity.
For Dr. Lawrie and her conversion with Dr Andrew Hill and " The assassination of Ivermectin and the death of millions".

Dr Jackie Stone describes on video how Zimbabwe's acceptance in January 2021 of ivermectin saved lives. Not only does Dr Stone describe her success with ivermectin but how she believes it acts on SARS-CoV-2. Ivermectin administration started in her clinic on 8th August. A colleague who ran a 22-bed hospital in an old-age care home was able to empty the hospital in six days, despite five of the patients being classed as 'critical' at the outset. In Dr Stone's own clinic two critical patients also survived and were discharged with oxygen for use at home. "One of them I really sent home for palliative care, with a very good nurse". A few days later she was astonished to be told that in spite of apparently poor blood chemistry - including a D-dimer level of 10,000 - the patient felt well and was walking round the garden. "From 8th August until 24th December I didn't lose a patient and if you look at our patient group, 26% of them [had oxygen saturations] of less than 80%", she said.
Her usual dosage is .2 grams per 5 Kg, but in cases of higher viral load she gives bigger dosage. She has found clients who misunderstand instructions and took a week's dosage at once without any side effects. She uses tablets when available otherwise the liquid form. She also describes her experience catching SARS-Cov-2 and taking ivermectin.

Dr John Campbell looks at the best ivermectin meta analysis and examination of bias.

Belgian Virologist proposes a plan to eradicate Covid-19 in 6 weeks using Ivermectin. Quoted is the analysis by Dr Tess Lawrie in the UK based on 15 randomised trials, including 4,000 patients. It reduces death by 83%, reducing the risk of deterioration by 53%. As prophylaxis to frontline workers and others exposed to the virus, particularly in households, reduces the risk of infection by 88%. The suggested dosage is .2 mg per kg for prophylaxis, then the second dose in 48 hours, then every two weeks. As to objections to the lack of an RDBPC, Dr Wathelet's counter-argument" "It would be foolish to wait for the slow and flawed peer-review process in the context of a pandemic when lives are at stake".

Slovakia Becomes the First EU Nation to Formally Approve Ivermectin for Both Prophylaxis and Treatment for COVID-19 Patients - January 28, 2021. The medicine will also be available at licensed prescription pharmacies.

Central American Nation of Belize Authorizes Use of Ivermectin for COVID-19 - December 24, 2020. The move basically represents a sort of pragmatic survival as a Latin American developing nation seeks answers to the pandemic.

Macedonia Pharmacies to Supply with Ivermectin for COVID-19 as MALMED Apparently Authorizes.

Portuguese doctors support Ivermectin to treat early signs of Covid-19. Portuguese doctors may be divided over the use of anti-parasitic medication Ivermectin to treat the early stages of Covid-19, but those that support it are adamant that it works.

Uttar Pradesh - which distributed free ivermectin for home care - had the second-lowest fatality rate in India at 0.26 per 100,000 residents in December. Only the state of Bihar, with 128 million residents, was lower, and it, too, recommends ivermectin. But Uttar Pradesh did more than treat 300,000 mild cases at home through 2020; it also opted to use ivermectin to prevent infection. It seems a young health officer's COVID response teams had taken the drug and remained well - something prophylaxis studies support. U.P. then had contacts of COVID patients take it, with similar success. "Recognising the sense of urgency," Amit Mohan Prasad, a U.P. health official, wrote in a Dec. 30 article, "we decided to go ahead."

Still no luck with Ivermectin

Whether ivermectin, with a maximum targeted dose of 600 µg/kg, shortens symptom duration or prevents hospitalization among outpatients with mild to moderate coronavirus disease 2019 (COVID-19) remains unknown.

The need and benefits of repurposing existing drugs and overcoming resistance

However there are as yet no peer reviewed randomized double-blind placebo-control (RDBPC) studies which are considered the "gold standard" of epidemiologic studies that are acceptable to Western medical bodies for repurposed drugs to cure Covid-19. One problem with RDBPC is their cost, which cost may be acceptable to a patented drug that could make its owners huge profits, but there are few volunteers to pay for an RDBPC for an existing drug to be used for treating a different or new disease where any laboratory can manufacture the drug.
It defies logic that a drug, ivermectin, that was used 3,7 billion times with its main side effect being the dying parasites it was treating causing side effects, considered a "safe" drug, should suddenly be "A concerning lack of safety data in the majority of studies" per Merck.
Many drugs that could work off-label can not and will not be used, and many lives lost because of this anomaly and others in our medical system.
Additionally, since so many patients suffer from the "long covid" effect where symptoms continue for an extended period, it would be surprising, given the anti-inflammatory and antiviral activity that it is later proven not just to combat the acute viral illness but also may be effective against the long covid.

People Died. The Establishment Played Games - Here's what it took, and how disgracefully long it took, for a simple COVID research project by Martin Makary MD, MPH, Editor-in-Chief, MedPage Today March 8, 2021.
"Our normal time and cycle for discovery and dissemination of information is way too freaking long. It's absurd, this idea of you put something in an abstract form, you submit it, then you sit back and relax and wait to hear back three months later, then the conference says, "Sure, you can present it next fall." Then you present it at the meeting, and then you submit it to a journal, then it goes into a queue, and a year and a half after the research discovery, the rest of the medical community learns about it in a peer-review publication. That's a disgrace, and it doesn't work during a health emergency."

Ivermectin has saved thousands of lives of Covid-19 sufferers worldwide. As an example of an intractable twentieth-century medical mindset, ivermectin was banned in South Africa, see below for the history of litigation. Authorities such as the South African Health Products Regulations Authority (Sahpra) reject new ideas without randomised, double-blind placebo-control (RDBPC) study, which takes money; the time delay will cost many thousands of lives. To quote, "Sahpra said there was no clinical evidence available for the use of Ivermectin in the management of Covid-19 infections." They have resisted its use or accepted its effectiveness without RDBPC evidence, and reports of its success in the real world are not evidence. Sahpra and other bodies will not accept the successful reports that many studies included were not peer-reviewed and meta-analyses are prone to confounding issues, plus many were in what could be termed third world countries where the resources for an RDBPC trial were limited.
"Meanwhile, Pfizer got their approval from studies done overseas, so it is hypocritical of our (USA) agencies of approving certain things that were done overseas and then not approving other things done overseas. See Dr Ryan Cole's presentation 16 minutes 30 Seconds in." Dr Cole also says that the cost in India is 2 cents a dose, although when compounded in America the cost is about $2 to $5 a dose.
However, with so much practical success with a low-cost drug that has such low side effects, its use should be encouraged, not scorned and denigrated.
For some reason, there seems to be a concentrated effort to knock down every low cost proposed Covid-19 relief.
Perhaps it is time for a faster, simpler authorisation system such as allowing registered repurposed drugs to be prescribed by registered medical professionals, even allowing health insurance funds to pay for the drugs.

Could there be any connection between promoting costly new drugs and rubbishing possibly effective patent expired old drugs?

Merck has issued a strongly worded official notification on 4 February 2021 that after extensive data review, "We do not believe that the data available support the safety and efficacy of ivermectin beyond the doses and populations indicated in the regulatory agency-approved prescribing information."

Perhaps as per the Sydney Morning Herald on 13 July 2021 the fact that the US government has already agreed to pay Merck & Co. $US1.2 billion (A$1.6 billion) for the company's own experimental antiviral molnupiravir if it clears regulators is causing Merck to have 1,2 billion reasons to rubbish its own patent expired ivermectin.

"The Mectizan Donation Program provides treatments with the clear understanding that donated Mectizan will only be used for these two diseases (onchocerciasis and lymphatic filariasis) through mass drug distribution programs. Use of donated Mectizan for any other indication and at unauthorized doses is strictly prohibited and can be dangerous." Source.
This conflicts with the WHO saying "Unlike previous treatments, which had serious - sometimes fatal - side effects, ivermectin is safe and can be used on a wide scale."

Is someone not being completely honest? So if the patient is dying from Covid-19 and the doctor has Mectizan donated ivermectin for river blindness in his bag, the doctor dare not use the ivermectin. Interesting ethical medical advice!

FLCCC to Merck: The Data Shows Ivermectin's Strong Efficacy Against COVID-19. By FLCCC Feb 16, 2021 Updated Feb 18, 2021.
Dr Pierre Kory, President and Chief Medical Officer of the FLCCC, said that "The company's disregard for the most current medical evidence is an evidentiary indictment of their uncorroborated position. Merck's press release will cause governments, health authorities, medical providers, business leaders, and citizens to retreat from pursuing a medical agent that, according to our recent peer-reviewed and accepted publication to the highly regarded Frontiers in Pharmacology, has been proven to be an effective and globally available agent to prevent and treat every phase of COVID-19 disease."

"Merck shuts down Covid vaccine program MK-4482/MK-7110 after early trial data showed they failed to generate immune responses comparable to a natural infection or existing vaccines. By Riley Griffin, Bloomberg 25 Jan 2021"
Until January 2021 Merck was developing its own Covid vaccine. Could it be thought that falling mortality from the use of ivermectin would reduce demand for vaccine? Surely not! We are talking about 100s of thousands of lives v big profits.

It should be noted that Merck has put a lot of money into patent-protected molnupiravir (also known as EIDD-2801), described as last of the small molecule coronavirus hopes and wants to prioritise this drugs.
Antiviral drug 'Molnupiravir' blocks Covid-19 virus within 24 hours: Study "This is the first demonstration of an orally available drug to rapidly block SARS-CoV-2 transmission. MK-4482/EIDD-2801 could be game-changing," said study author Richard Plemper from GSU.

Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19.

The U.S. government has agreed to purchase a minimum of 100,000 doses of bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together, for $210 million and doses will be delivered through March 31, 2021. That is at a cost of $2,100 per dose. Eli Lilly and Company (NYSE: LLY) announced. Bamlanivimab and etesevimab together recently received emergency use authorization for the treatment of recently diagnosed, mild to moderate COVID-19 in patients who are at high risk of progressing to severe COVID-19 and/or hospitalization. Additionally, the National Institutes of Health (NIH) recently updated the COVID-19 Treatment Guidelines to recommend the use of bamlanivimab plus etesevimab for the treatment of outpatients with mild to moderate COVID-19 who are at high risk of clinical progression.
Authors note. That would appear to be about 420 times (42,000%) more costly than ivermectin which almost certainly does the same thing. No wonder there is pressure to denigrate ivermectin!!

"It is difficult to get a man to understand something when his salary depends upon his not understanding it." - Upton Sinclair

Questioning the resistance to drug repurposing

Watch the SPARK Drug Repurposing Conference Tel Aviv University Oct 2020 webinar here. Prof. Dan Peer, director of Spark and vice president of R&D at Tel Aviv University, urges governments across the world to create task forces focused on drug repurposing. "Spark's mission is to bring drugs as quickly and efficiently as possible to the clinic." "New therapeutics and diagnostics, repurposing of existing drugs and new entities for incurable diseases can save billions of dollars and many years in development by using a pool of thousands of FDA-approved drugs. We should be able to solve the problem of Covid-19 by overcoming bureaucratic red tape and financial barriers to new drug development."
"Of the 9,000 currently approved drugs that exist globally, the potential for overcoming Covid-19 certainly exists, " said the event organisers. "Instead of reinventing the wheel, we need to harness efforts to identify existing drugs that can treat Covid-19, select the safest ones, and validate their efficacy utilising rapid evaluation methods tailored to times of crisis."
The drugs to fight Covid-19 are already on the market. Israeli experts say there's no need to reinvent the wheel, drug repurposing may be the fastest and cheapest way to treat people infected with the novel coronavirus. Peer and Rogosnitzky urge governments across the world to create task forces focused on drug repurposing.

Ivermectin Triple Therapy Protocol for COVID-19 Released to Australian GPs for Infected Elderly and Frontline Workers. "The three medications are on chemist shelves right now. GPs can email GP@CDD.com.au to obtain the dosing protocol and COVID-19 treatment information for their patients. Professor Borody continued: "GPs can legally prescribe the therapy today as an "off label" treatment according to Australian Guidelines - a standard practice in medicine. More than 60% of prescriptions in Australia are "off-label". It's not a new concept. It's happening every day to manage diseases and save lives."

January 20, 2021, Paul Sax, MD, a professor of medicine at Harvard and clinical director of the HIV Program and Division of Infectious Diseases at Brigham and Women's Hospital in Boston, wrote in a blog post earlier this month in the New England Journal of Medicine Journal that ivermectin has more robust evidence for it than HCQ ever did. "But we're not quite yet at the 'practice changing' level," he writes. "Results from at least five randomised clinical trials are expected soon that might further inform the decision," Sax advises against two biases in considering ivermectin. First, one is assuming that because HCQ failed, (a questionable assumption) other antiparasitic drugs will too. The second bias to avoid, he says, is discounting studies done in low- and middle-income countries because "they weren't done in the right places." "That's not just bias," he says. "It's also snobbery."

Bill and Melinda Gates Fund Global Ivermectin and Fluvoxamine Clinical Trial targeting Covid-19 titled the Together Covid-19 trial. Participating is Canada, Brazil, South Africa's University of Stellenbosch and sites in the USA. When announced this trial drew cynical comments similar to - "Funding to discredit it or promote? We shall see." and "Will this involve another deliberately flawed and /or fraudulent study as for hydroxychloroquine?"

Comparing the results from two similar double-blind, randomized trials by Sheba (the 9th best hospital in the world) and in Cali, Colombia we get different conclusions from similar trials.

Link to pdf created from Prof Eli Schwartz pre-presentation video.